|
Phenotype
|
Fish
|
Conditions
|
Figures
|
|
whole organism acrolein increased amount, abnormal
|
akr1a1azf3750/zf3750
|
standard conditions
|
Fig. 1
from Li et al., 2026
|
|
blood glucose increased amount, abnormal
|
akr1a1azf3750/zf3750
|
feeding regime
|
Fig. 5
from Li et al., 2026
|
|
glucose homeostasis disrupted, abnormal
|
akr1a1azf3750/zf3750
|
feeding regime
|
Fig. 5
from Li et al., 2026
|
|
podocyte podocyte foot increased width, abnormal
|
akr1a1azf3750/zf3750
|
standard conditions
|
Fig. 5
from Li et al., 2026
|
|
whole organism glucose increased amount, abnormal
|
akr1a1azf3750/zf3750
|
standard conditions
|
Fig. 5
from Li et al., 2026
|
|
glucose homeostasis disrupted, abnormal
|
akr1a1azf3750/zf3750
|
standard conditions
|
Fig. 5
from Li et al., 2026
|
|
glomerular basement membrane increased thickness, abnormal
|
akr1a1azf3750/zf3750
|
standard conditions
|
Fig. 5
from Li et al., 2026
|
|
liver insrb expression decreased amount, abnormal
|
akr1a1azf3750/zf3750; y1Tg
|
standard conditions
|
Figure 4
from Qi et al., 2021
|
|
whole organism ab5-akt labeling decreased amount, abnormal
|
akr1a1azf3750/zf3750; y1Tg
|
chemical treatment by environment: acrolein
|
Figure 7
from Qi et al., 2021
|
|
blood glucose increased amount, abnormal
|
akr1a1azf3750/zf3750; y1Tg
|
food availability
|
Figure 4
from Qi et al., 2021
|
|
whole organism insrb expression decreased amount, abnormal
|
akr1a1azf3750/zf3750; y1Tg
|
chemical treatment by environment: acrolein
|
Figure 6
from Qi et al., 2021
|
|
whole organism insra expression decreased amount, abnormal
|
akr1a1azf3750/zf3750; y1Tg
|
standard conditions
|
Figure 4 ,
Figure 6
from Qi et al., 2021
|
|
whole organism ab3-akt labeling increased amount, abnormal
|
akr1a1azf3750/zf3750; y1Tg
|
chemical treatment by environment: acrolein
|
Figure 7
from Qi et al., 2021
|
|
liver acrolein increased amount, abnormal
|
akr1a1azf3750/zf3750; y1Tg
|
standard conditions
|
Figure 4
from Qi et al., 2021
|
|
liver phosphofructokinase activity decreased process quality, abnormal
|
akr1a1azf3750/zf3750; y1Tg
|
standard conditions
|
Figure 4
from Qi et al., 2021
|
|
hyaloid vessel increased branchiness, abnormal
|
akr1a1azf3750/zf3750; y1Tg
|
chemical treatment by environment: acrolein
|
Figure 6
from Qi et al., 2021
|
|
liver pyruvic acid decreased amount, abnormal
|
akr1a1azf3750/zf3750; y1Tg
|
standard conditions
|
Figure 4
from Qi et al., 2021
|
|
whole organism NADP+ biosynthetic process decreased process quality, abnormal
|
akr1a1azf3750/zf3750; y1Tg
|
standard conditions
|
Figure 1 ,
Figure 4
from Qi et al., 2021
|
|
whole organism insra expression decreased amount, abnormal
|
akr1a1azf3750/zf3750; y1Tg
|
chemical treatment by environment: acrolein
|
Figure 6
from Qi et al., 2021
|
|
whole organism ab3-akt labeling increased amount, abnormal
|
akr1a1azf3750/zf3750; y1Tg
|
control
|
Figure 7
from Qi et al., 2021
|
|
whole organism acrolein increased amount, abnormal
|
akr1a1azf3750/zf3750; y1Tg
|
standard conditions
|
Figure 4
from Qi et al., 2021
|
|
glomerular basement membrane increased thickness, abnormal
|
akr1a1azf3750/zf3750; y1Tg
|
standard conditions
|
Figure 2
from Qi et al., 2021
|
|
whole organism ab5-akt labeling decreased amount, abnormal
|
akr1a1azf3750/zf3750; y1Tg
|
control
|
Figure 7
from Qi et al., 2021
|
|
hyaloid vessel sprouting angiogenesis increased process quality, abnormal
|
akr1a1azf3750/zf3750; y1Tg
|
standard conditions
|
Figure 2
from Qi et al., 2021
|
|
hyaloid vessel increased branchiness, abnormal
|
akr1a1azf3750/zf3750; y1Tg
|
standard conditions
|
Figure 2 ,
Figure 6
from Qi et al., 2021
|
|
whole organism ins expression decreased amount, abnormal
|
akr1a1azf3750/zf3750; y1Tg
|
standard conditions
|
Figure 4
from Qi et al., 2021
|
|
liver akr1a1a expression absent, abnormal
|
akr1a1azf3750/zf3750; y1Tg
|
standard conditions
|
Figure 1
from Qi et al., 2021
|
|
whole organism glucose increased amount, abnormal
|
akr1a1azf3750/zf3750; y1Tg
|
standard conditions
|
Figure 4
from Qi et al., 2021
|
|
whole organism insrb expression decreased amount, abnormal
|
akr1a1azf3750/zf3750; y1Tg
|
standard conditions
|
Figure 4 ,
Figure 6
from Qi et al., 2021
|
|
liver insra expression decreased amount, abnormal
|
akr1a1azf3750/zf3750; y1Tg
|
standard conditions
|
Figure 4
from Qi et al., 2021
|
|
whole organism phosphatidylinositol 3-kinase/protein kinase B signal transduction increased magnitude, abnormal
|
glo1zf3029/zf3029; akr1a1azf3750/zf3750
|
chemical treatment by environment: arginine
|
Fig. 6
from Li et al., 2026
|
|
whole organism gck expression decreased amount, abnormal
|
glo1zf3029/zf3029; akr1a1azf3750/zf3750
|
standard conditions
|
Fig. 4
from Li et al., 2026
|
|
whole organism ins expression increased amount, abnormal
|
glo1zf3029/zf3029; akr1a1azf3750/zf3750
|
chemical treatment by environment: arginine
|
Fig. 6
from Li et al., 2026
|
|
whole organism insulin decreased amount, abnormal
|
glo1zf3029/zf3029; akr1a1azf3750/zf3750
|
standard conditions
|
Fig. 6
from Li et al., 2026
|
|
kidney col4a4 expression increased amount, abnormal
|
glo1zf3029/zf3029; akr1a1azf3750/zf3750
|
standard conditions
|
Fig. 5
from Li et al., 2026
|
|
whole organism ins expression decreased amount, abnormal
|
glo1zf3029/zf3029; akr1a1azf3750/zf3750
|
standard conditions
|
Fig. 4
from Li et al., 2026
|
|
kidney col4a3 expression increased amount, abnormal
|
glo1zf3029/zf3029; akr1a1azf3750/zf3750
|
standard conditions
|
Fig. 5
from Li et al., 2026
|
|
whole organism insrb expression increased amount, abnormal
|
glo1zf3029/zf3029; akr1a1azf3750/zf3750
|
chemical treatment by environment: arginine
|
Fig. 6
from Li et al., 2026
|
|
liver arg1 expression decreased amount, abnormal
|
glo1zf3029/zf3029; akr1a1azf3750/zf3750
|
standard conditions
|
Fig. 4
from Li et al., 2026
|
|
liver odc1 expression decreased amount, abnormal
|
glo1zf3029/zf3029; akr1a1azf3750/zf3750
|
standard conditions
|
Fig. 4
from Li et al., 2026
|
|
glucose homeostasis disrupted, abnormal
|
glo1zf3029/zf3029; akr1a1azf3750/zf3750
|
feeding regime
|
Fig. 5
from Li et al., 2026
|
|
whole organism imidazolinone increased amount, abnormal
|
glo1zf3029/zf3029; akr1a1azf3750/zf3750
|
standard conditions
|
Fig. 2
from Li et al., 2026
|
|
podocyte podocyte foot increased width, exacerbated
|
glo1zf3029/zf3029; akr1a1azf3750/zf3750
|
standard conditions
|
Fig. 5
from Li et al., 2026
|
|
whole organism glucose decreased amount, abnormal
|
glo1zf3029/zf3029; akr1a1azf3750/zf3750
|
chemical treatment by environment: arginine
|
Fig. 6
from Li et al., 2026
|
|
whole organism acrolein increased amount, abnormal
|
glo1zf3029/zf3029; akr1a1azf3750/zf3750
|
standard conditions
|
Fig. 1
from Li et al., 2026
|
|
glomerular basement membrane increased thickness, exacerbated
|
glo1zf3029/zf3029; akr1a1azf3750/zf3750
|
standard conditions
|
Fig. 5
from Li et al., 2026
|
|
liver insrb expression decreased amount, abnormal
|
glo1zf3029/zf3029; akr1a1azf3750/zf3750
|
standard conditions
|
Fig. 4
from Li et al., 2026
|
|
whole organism slc2a2 expression decreased amount, abnormal
|
glo1zf3029/zf3029; akr1a1azf3750/zf3750
|
standard conditions
|
Fig. 4
from Li et al., 2026
|
|
whole organism insra expression increased amount, abnormal
|
glo1zf3029/zf3029; akr1a1azf3750/zf3750
|
chemical treatment by environment: arginine
|
Fig. 6
from Li et al., 2026
|
|
liver arginine decreased amount, abnormal
|
glo1zf3029/zf3029; akr1a1azf3750/zf3750
|
standard conditions
|
Fig. 2
from Li et al., 2026
|
|
kidney lamb1a expression increased amount, abnormal
|
glo1zf3029/zf3029; akr1a1azf3750/zf3750
|
standard conditions
|
Fig. 5
from Li et al., 2026
|
|
blood glucose increased amount, exacerbated
|
glo1zf3029/zf3029; akr1a1azf3750/zf3750
|
feeding regime
|
Fig. 5
from Li et al., 2026
|
|
whole organism slc2a8 expression increased amount, abnormal
|
glo1zf3029/zf3029; akr1a1azf3750/zf3750
|
chemical treatment by environment: arginine
|
Fig. 6
from Li et al., 2026
|
|
liver asl expression decreased amount, abnormal
|
glo1zf3029/zf3029; akr1a1azf3750/zf3750
|
standard conditions
|
Fig. 4
from Li et al., 2026
|
|
whole organism ugp2a expression increased amount, abnormal
|
glo1zf3029/zf3029; akr1a1azf3750/zf3750
|
chemical treatment by environment: arginine
|
Fig. 6
from Li et al., 2026
|
|
whole organism phosphatidylinositol 3-kinase/protein kinase B signal transduction decreased magnitude, abnormal
|
glo1zf3029/zf3029; akr1a1azf3750/zf3750
|
standard conditions
|
Fig. 6
from Li et al., 2026
|
|
liver slc7a1a expression increased amount, abnormal
|
glo1zf3029/zf3029; akr1a1azf3750/zf3750
|
standard conditions
|
Fig. 4
from Li et al., 2026
|
|
whole organism gck expression increased amount, abnormal
|
glo1zf3029/zf3029; akr1a1azf3750/zf3750
|
chemical treatment by environment: arginine
|
Fig. 6
from Li et al., 2026
|
|
whole organism gys1 expression decreased amount, abnormal
|
glo1zf3029/zf3029; akr1a1azf3750/zf3750
|
standard conditions
|
Fig. 4
from Li et al., 2026
|
|
whole organism arginine decreased amount, abnormal
|
glo1zf3029/zf3029; akr1a1azf3750/zf3750
|
standard conditions
|
Fig. 2
from Li et al., 2026
|
|
liver slc7a1b expression increased amount, abnormal
|
glo1zf3029/zf3029; akr1a1azf3750/zf3750
|
standard conditions
|
Fig. 4
from Li et al., 2026
|
|
liver ins expression decreased amount, abnormal
|
glo1zf3029/zf3029; akr1a1azf3750/zf3750
|
standard conditions
|
Fig. 4
from Li et al., 2026
|
|
whole organism glucose amount, ameliorated
|
glo1zf3029/zf3029; akr1a1azf3750/zf3750
|
chemical treatment by environment: arginine, chemical treatment by environment: N(gamma)-nitro-L-arginine methyl ester
|
Fig. 6
from Li et al., 2026
|
|
kidney lama1 expression increased amount, abnormal
|
glo1zf3029/zf3029; akr1a1azf3750/zf3750
|
standard conditions
|
Fig. 5
from Li et al., 2026
|
|
whole organism pkmb expression decreased amount, abnormal
|
glo1zf3029/zf3029; akr1a1azf3750/zf3750
|
standard conditions
|
Fig. 4
from Li et al., 2026
|
|
whole organism insrb expression decreased amount, abnormal
|
glo1zf3029/zf3029; akr1a1azf3750/zf3750
|
standard conditions
|
Fig. 4
from Li et al., 2026
|
|
whole organism methylglyoxal increased amount, abnormal
|
glo1zf3029/zf3029; akr1a1azf3750/zf3750
|
standard conditions
|
Fig. 1
from Li et al., 2026
|
|
muscle phosphatidylinositol 3-kinase/protein kinase B signal transduction decreased magnitude, abnormal
|
glo1zf3029/zf3029; akr1a1azf3750/zf3750
|
feeding regime
|
Fig. 4
from Li et al., 2026
|
|
whole organism glucose increased amount, exacerbated
|
glo1zf3029/zf3029; akr1a1azf3750/zf3750
|
standard conditions
|
Fig. 5
from Li et al., 2026
|
|
whole organism slc2a8 expression decreased amount, abnormal
|
glo1zf3029/zf3029; akr1a1azf3750/zf3750
|
standard conditions
|
Fig. 4
from Li et al., 2026
|
|
liver gys1 expression decreased amount, abnormal
|
glo1zf3029/zf3029; akr1a1azf3750/zf3750
|
standard conditions
|
Fig. 4
from Li et al., 2026
|
|
glucose homeostasis disrupted, abnormal
|
glo1zf3029/zf3029; akr1a1azf3750/zf3750
|
standard conditions
|
Fig. 5
from Li et al., 2026
|
|
liver phosphatidylinositol 3-kinase/protein kinase B signal transduction decreased magnitude, abnormal
|
glo1zf3029/zf3029; akr1a1azf3750/zf3750
|
feeding regime
|
Fig. 4
from Li et al., 2026
|
|
whole organism ugp2a expression decreased amount, abnormal
|
glo1zf3029/zf3029; akr1a1azf3750/zf3750
|
standard conditions
|
Fig. 4
from Li et al., 2026
|
|
whole organism slc2a2 expression increased amount, abnormal
|
glo1zf3029/zf3029; akr1a1azf3750/zf3750
|
chemical treatment by environment: arginine
|
Fig. 6
from Li et al., 2026
|
|
whole organism insulin amount, ameliorated
|
glo1zf3029/zf3029; akr1a1azf3750/zf3750
|
chemical treatment by environment: arginine
|
Fig. 6
from Li et al., 2026
|
|
kidney col4a5 expression increased amount, abnormal
|
glo1zf3029/zf3029; akr1a1azf3750/zf3750
|
standard conditions
|
Fig. 5
from Li et al., 2026
|
|
liver ass1 expression decreased amount, abnormal
|
glo1zf3029/zf3029; akr1a1azf3750/zf3750
|
standard conditions
|
Fig. 4
from Li et al., 2026
|
|
liver insra expression decreased amount, abnormal
|
glo1zf3029/zf3029; akr1a1azf3750/zf3750
|
standard conditions
|
Fig. 4
from Li et al., 2026
|